FGFR4 inhibitor

This page covers all FGFR4 inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting FGFR4.

Targets

FGFR4

Phase 2 pipeline (1)

• AZD5004 · AstraZeneca · Oncology
  AZD5004 is a selective inhibitor of fibroblast growth factor receptor 4 (FGFR4) that blocks aberrant FGF signaling in hepatocellular carcinoma and other cancers.